On September 21, 2017, the Comprehensive Economic and Trade Agreement (CETA) signed between the European Union (EU) and Canada provisionally entered into force in Canada. Among other things, this agreement seeks to harmonize laws relating to protection of intellectual property in the EU and Canada, thereby bringing about a number of changes in Canadian patent law, particularly with respect to laws relating to the issuance of patents covering pharmaceutical products. One of the biggest changes is the implementation of a Certificate of Supplementary Protection (CSP) Regime in Canada for pharmaceutical products that have been granted regulatory approval.
Alex is a registered patent attorney who advises clients on matters pertaining to patent prosecution and patent portfolio management. He regularly performs prior art, landscape, and freedom-to-operate searches as part of his evaluation of patentability and freedom-to-operate issues, and prepares patentability, validity, and freedom-to-operate opinions for portfolio analyses and investment due diligence. Although his practice focuses primarily on chemistry — including pharmaceuticals, chemicals (organic, inorganic, and organometallic), materials, and polymers — Alex also has experience with biotechnology (assays, PCR), polymeric drug delivery methods, fuel cell materials, and nanotechnology.